Brief: Pharnext: Financing Agreement With Néovacs For EUR 20.7 Mln Net To Further Develop PXT3003

Neovacs SA

03/10/2022 17:12

Oct 3 (Reuters) - Pharnext SA  PHARN.PA :
    * PHARNEXT EXECUTES A FINANCING AGREEMENT WITH NÉOVACS FOR
EUR
20.7 MILLION NET TO FURTHER DEVELOP PXT3003 FOR
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
    * CUMULATIVE FINANCING RESULTING FROM THESE AGREEMENTS
BRINGS A
TOTAL POTENTIALLY AVAILABLE NET AMOUNT OF APPROXIMATELY EUR 46.7
MILLION
    * SUBJECT TO EACH PARTY'S SATISFYING ITS OBLIGATIONS,
CONSIDERS IT
WOULD BE ABLE TO FINANCE ITS OPERATIONS, PREMIER TRIAL UNTIL Q1
2024

Source text for Eikon:  ID:nEQ2n0MB7a 
Further company coverage:  PHARN.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))